Y-mAbs Therapeutics Inc
NASDAQ:YMAB
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.44
18.69
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one YMAB stock under the Base Case scenario is 15.75 USD. Compared to the current market price of 10.41 USD, Y-mAbs Therapeutics Inc is Undervalued by 34%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Y-mAbs Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for YMAB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Y-mAbs Therapeutics Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Y-mAbs Therapeutics Inc
Balance Sheet Decomposition
Y-mAbs Therapeutics Inc
Current Assets | 99.1m |
Cash & Short-Term Investments | 68.1m |
Receivables | 19.9m |
Other Current Assets | 11m |
Non-Current Assets | 21.9m |
PP&E | 1.1m |
Intangibles | 2.4m |
Other Non-Current Assets | 18.4m |
Current Liabilities | 25.3m |
Accounts Payable | 7.9m |
Accrued Liabilities | 17.4m |
Non-Current Liabilities | 3.2m |
Other Non-Current Liabilities | 3.2m |
Earnings Waterfall
Y-mAbs Therapeutics Inc
Revenue
|
84.6m
USD
|
Cost of Revenue
|
-9.4m
USD
|
Gross Profit
|
75.2m
USD
|
Operating Expenses
|
-103.6m
USD
|
Operating Income
|
-28.5m
USD
|
Other Expenses
|
4.6m
USD
|
Net Income
|
-23.9m
USD
|
Free Cash Flow Analysis
Y-mAbs Therapeutics Inc
USD | |
Free Cash Flow | USD |
YMAB Profitability Score
Profitability Due Diligence
Y-mAbs Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Y-mAbs Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
YMAB Solvency Score
Solvency Due Diligence
Y-mAbs Therapeutics Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
Y-mAbs Therapeutics Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
YMAB Price Targets Summary
Y-mAbs Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for YMAB is 21.33 USD with a low forecast of 11.11 USD and a high forecast of 27.3 USD.
Dividends
Current shareholder yield for YMAB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
YMAB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in New York City, New York and currently employs 148 full-time employees. The company went IPO on 2018-09-21. The company is focused on development and commercialization of antibody based therapeutic products for the treatment of cancer. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The Company’s product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and omburtamab, which targets tumors that express B7-H3. DANYELZA, which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. The company also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The firm is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.
Contact
IPO
Employees
Officers
The intrinsic value of one YMAB stock under the Base Case scenario is 15.75 USD.
Compared to the current market price of 10.41 USD, Y-mAbs Therapeutics Inc is Undervalued by 34%.